Compare Stocks: FBLG, CELU, MGX, and IZTC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.34 -4.8%	$0.97	$0.56 ▼ $2.55	$39.08M	0.79	1.52 million shs	129,870 shs
FBLG FibroBiologics	$1.59 -1.4%	$1.13	$0.62 ▼ $12.40	$10.58M	1.65	259,576 shs	36,949 shs
IZTC Invizyne Technologies	$6.30 +2.1%	$6.15	$8.50 ▼ $23.00	$39.40M	N/A	37,647 shs	4,558 shs
MGX Metagenomi	$1.18 +1.7%	$1.22	$1.13 ▼ $3.95	$44.58M	0.67	200,824 shs	78,052 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	-16.07%	+102.64%	+83.12%	-39.22%
FBLG FibroBiologics	0.00%	-11.05%	+51.89%	+80.29%	-85.17%
IZTC Invizyne Technologies	0.00%	-8.01%	+5.03%	-11.25%	-49.18%
MGX Metagenomi	0.00%	-0.85%	-5.69%	-0.85%	-37.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$1.34 -4.8%	$0.97	$0.56 ▼ $2.55	$39.08M	0.79	1.52 million shs	129,870 shs
FBLG FibroBiologics	$1.59 -1.4%	$1.13	$0.62 ▼ $12.40	$10.58M	1.65	259,576 shs	36,949 shs
IZTC Invizyne Technologies	$6.30 +2.1%	$6.15	$8.50 ▼ $23.00	$39.40M	N/A	37,647 shs	4,558 shs
MGX Metagenomi	$1.18 +1.7%	$1.22	$1.13 ▼ $3.95	$44.58M	0.67	200,824 shs	78,052 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	0.00%	-16.07%	+102.64%	+83.12%	-39.22%
FBLG FibroBiologics	0.00%	-11.05%	+51.89%	+80.29%	-85.17%
IZTC Invizyne Technologies	0.00%	-8.01%	+5.03%	-11.25%	-49.18%
MGX Metagenomi	0.00%	-0.85%	-5.69%	-0.85%	-37.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	1.00	Sell	N/A	N/A
FBLG FibroBiologics	1.80	Reduce	$73.00	4,496.98% Upside
IZTC Invizyne Technologies	0.00	N/A	N/A	N/A
MGX Metagenomi	2.75	Moderate Buy	$6.00	408.47% Upside

Current Analyst Ratings Breakdown

Latest FBLG, CELU, MGX, and IZTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/4/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/27/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/12/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$7.00
8/5/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/4/2026	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00 ➝ $6.00
8/4/2026	FBLG FibroBiologics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Underperform
7/24/2026	FBLG FibroBiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$26.55M	1.46	N/A	N/A	($1.32) per share	-1.02
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$1.85 per share	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	$25.21M	1.77	N/A	N/A	$4.22 per share	0.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$91.72M	-$3.33	N/A	N/A	N/A	-345.45%	N/A	-77.94%	11/13/2026 (Estimated)
FBLG FibroBiologics	-$18.65M	-$5.19	N/A	N/A	N/A	N/A	-536.78%	-225.12%	10/30/2026 (Estimated)
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	-$87.87M	-$2.49	N/A	N/A	N/A	-384.61%	-63.65%	-44.52%	11/10/2026 (Estimated)

Latest FBLG, CELU, MGX, and IZTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/10/2026	Q2 2026	MGX Metagenomi	-$0.5531	-$0.73	-$0.1769	-$0.73	$3.01 million	($0.26) million
7/31/2026	Q2 2026	FBLG FibroBiologics	-$0.93	-$0.66	+$0.27	-$0.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	N/A	0.15	0.15
FBLG FibroBiologics	N/A	2.64	2.64
IZTC Invizyne Technologies	N/A	N/A	N/A
MGX Metagenomi	N/A	4.50	4.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
FBLG FibroBiologics	N/A
IZTC Invizyne Technologies	N/A
MGX Metagenomi	N/A

Insider Ownership

Company	Insider Ownership
CELU Celularity	17.30%
FBLG FibroBiologics	7.30%
IZTC Invizyne Technologies	N/A
MGX Metagenomi	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	220	28.95 million	23.94 million	Optionable
FBLG FibroBiologics	10	6.66 million	6.17 million	N/A
IZTC Invizyne Technologies	29	6.25 million	N/A	N/A
MGX Metagenomi	236	37.78 million	33.06 million	N/A

FBLG, CELU, MGX, and IZTC Headlines

Recent News About These Companies

Metagenomi (NASDAQ:MGX) Director Laurence Reid Purchases 20,000 Shares of Stock

September 12 at 7:06 AM | insidertrades.com

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

September 1, 2026 | globenewswire.com

Metagenomi Therapeutics Inc MGX

August 25, 2026 | morningstar.comM

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

August 25, 2026 | prnewswire.com

MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript

August 20, 2026 | seekingalpha.com

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

August 11, 2026 | theglobeandmail.com

Metagenomi Therapeutics: Q2 Earnings Snapshot

August 10, 2026 | chron.com

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

August 10, 2026 | markets.businessinsider.com

Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates

August 10, 2026 | zacks.com

MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript

July 20, 2026 | seekingalpha.com

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

July 15, 2026 | globenewswire.com

Metagenomi Announces Board Changes and Shareholder Meeting Results

June 10, 2026 | tipranks.com

Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

June 5, 2026 | prnewswire.com

Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference

May 28, 2026 | globenewswire.com

Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50

May 14, 2026 | msn.com

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates

May 14, 2026 | finance.yahoo.com

Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 12, 2026 | markets.businessinsider.com

Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates

May 11, 2026 | zacks.com

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing ...

April 16, 2026 | markets.businessinsider.com

Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency

April 16, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, CELU, MGX, and IZTC Company Descriptions

Celularity NASDAQ:CELU

$1.34 -0.07 (-4.82%)

As of 11:36 AM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

FibroBiologics NASDAQ:FBLG

$1.59 -0.02 (-1.37%)

As of 11:36 AM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Invizyne Technologies NASDAQ:IZTC

$6.30 +0.13 (+2.13%)

As of 09/11/2026

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Metagenomi NASDAQ:MGX

$1.18 +0.02 (+1.72%)

As of 11:31 AM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBLG, CELU, MGX, and IZTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBLG, CELU, MGX, and IZTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBLG, CELU, MGX, and IZTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, CELU, MGX, and IZTC Company Descriptions

Celularity NASDAQ:CELU

FibroBiologics NASDAQ:FBLG

Invizyne Technologies NASDAQ:IZTC

Metagenomi NASDAQ:MGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FBLG, CELU, MGX, and IZTC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FBLG, CELU, MGX, and IZTC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FBLG, CELU, MGX, and IZTC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, CELU, MGX, and IZTC Company Descriptions

Celularity NASDAQ:CELU

FibroBiologics NASDAQ:FBLG

Invizyne Technologies NASDAQ:IZTC

Metagenomi NASDAQ:MGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools